- Home
- CGNT vs PHAR Comparison
CGNT vs PHAR Comparison
Compare CGNT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGNT | PHAR |
|---|---|---|
| Founded | 2020 | 1988 |
| Country | Israel | Netherlands |
| Employees | N/A | 409 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 768.2M | 917.4M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGNT | PHAR |
|---|---|---|
| Price | $11.49 | $13.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 594.9K | 12.3K |
| Earning Date | 06-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.73 | $10.04 |
| Revenue Next Year | $10.45 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.29 | $9.54 |
| 52 Week High | $11.66 | $21.34 |
Technical Indicators
Market Signals| Indicator | CGNT | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 69.42 | 40.26 |
| Support Level | $8.02 | $12.98 |
| Resistance Level | N/A | $13.44 |
| Average True Range (ATR) | 0.49 | 0.45 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 98.39 | 65.80 |
Price Performance
Historical ComparisonAbout CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PHAR Pharming Group N.V.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.